| Arlington Physical Therapy | |
|
5584 Airline Rd Ste 101, Arlington, TN 38002-9528 | |
| (901) 317-7054 | |
| (901) 317-7064 |
| Full Name | Arlington Physical Therapy |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 5584 Airline Rd Ste 101, Arlington, Tennessee |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750615373 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | PT0000007321 (Tennessee) | Primary |
| Provider Name | Matthew C Connell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1538398615 PECOS PAC ID: 8224167036 Enrollment ID: I20100603000230 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Provider Name | Jessica Rhoades |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1093122889 PECOS PAC ID: 3072832500 Enrollment ID: I20150505002913 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Provider Name | Julianne S Bell |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1598096786 PECOS PAC ID: 6002136819 Enrollment ID: I20150519001421 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Provider Name | Brendan D Bradley |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1902418155 PECOS PAC ID: 8022438720 Enrollment ID: I20201019002553 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Provider Name | Austin S Gwaltney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1770275125 PECOS PAC ID: 4688031362 Enrollment ID: I20230612002068 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Provider Name | Stephanie L Maddox |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1578751616 PECOS PAC ID: 9335236306 Enrollment ID: I20230727003087 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Arlington Physical Therapy 5584 Airline Rd Ste 101, Arlington, TN 38002-9528 Ph: (901) 317-7054 | Arlington Physical Therapy 5584 Airline Rd Ste 101, Arlington, TN 38002-9528 Ph: (901) 317-7054 |
News Archive
The Icahn School of Medicine at Mount Sinai today announced the publication of two papers in the journal Nature that reveal new information about the genetic complexity underpinning schizophrenia. These collaborative studies represent the largest exome sequencing efforts to date to elucidate this mental illness, and together found that the disorder is likely caused by far more rare genetic mutations than previously suspected.
Hyperbaric treatment for children with autism has reportedly led to improvements in the condition, though previous studies were uncontrolled.
Researchers have found that a newly developed drug, which is aimed at a particular receptor involved in the development of blood vessels that sustain tumour growth, is active in patients with advanced cancers and, in some cases, has halted the progress of the disease. The drug, ACE-041, targets a different molecular pathway to other anti-angiogenesis drugs and may provide a new option to treat cancer.
NPS Pharmaceuticals, Inc. today announced the closing of a public offering of 7,912,000 shares of its common stock, including 1,032,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the underwriters. Net proceeds were approximately $44.4 million after deducting underwriting discounts and estimated offering expenses. Jefferies & Company, Inc. acted as the sole book-running manager and Canaccord Genuity Inc. acted as co-lead manager for the offering.
New research findings show that embryonic stem cells unable to fully compact the DNA inside them cannot complete their primary task: differentiation into specific cell types that give rise to the various types of tissues and structures in the body.
› Verified 9 days ago
Tennessee Department Of Intellectual And Developmental Disabilities Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 11437 Milton Wilson Rd, Didd West Tn Seating And Positioning Clinic, Arlington, TN 38002 Phone: 901-745-7509 | |
Mr. Matthew John Coats, PT, OCS Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 6050 Airline Rd Ste 106, Arlington, TN 38002 Phone: 901-867-8989 | |
Cole Pediatric Therapy Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 12370 Strong Heart Trl, Arlington, TN 38002 Phone: 901-482-3997 | |
Karen Kay Sisco, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 11315 Mccormick Rd, Arlington, TN 38002 Phone: 901-292-5313 Fax: 901-867-3340 | |
Lisa A Lombard, MPT DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 6050 Airline Rd, Ste. 106, Arlington, TN 38002 Phone: 901-867-8989 Fax: 901-867-8757 | |
Morgan Jackson, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 9263 Osborn Rd, Arlington, TN 38002 Phone: 901-496-1057 | |
Pediatric Therapy Service Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 11315 Mccormick Rd, Arlington, TN 38002 Phone: 901-292-5313 |